BristolMyers Squibb Company
Open
$59.94
Prev. Close
$59.94
High
$59.94
Low
$59.83
Market Snapshot
$117.24B
16.6
-4.42
$48.3B
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 32,500 full-time employees. The company is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
emptyResult
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 32,500 full-time employees. The company is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
Recently from Cashu
Bristol-Myers Squibb Confronts Revenue Decline and Intensified Market Competition Challenges
Bristol-Myers Squibb Faces Challenges in Drug Performance and Market Competition Bristol-Myers Squibb (BMY) navigates a tumultuous period marked by significant challenges affecting its core pharmaceut…
Bristol-Myers Squibb Advances AI Integration to Transform Drug Development and Enhance Patient Outcomes
Bristol-Myers Squibb Strengthens Focus on AI Innovations in Drug Development Bristol-Myers Squibb (BMS) is increasingly emphasizing the integration of artificial intelligence (AI) in its drug discover…
BioNTech Advances mRNA Technology to Transform Healthcare and Personalize Cancer Treatments
BioNTech’s Commitment to Transformative Healthcare Solutions BioNTech continues to forge ahead in its mission to revolutionize healthcare with its innovative mRNA technology, particularly in the criti…
Gene Therapy Investment Trends Reflect Optimism in Biotechnology Sector's Future
Growing Trends in Gene Therapy Investment Reflect Industry Optimism Recent financial maneuvers in the biotechnology sector indicate a significant bullish sentiment towards gene therapy companies, exem…